NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant™
Key takeaways
- (NPCE) Reveals FDA Approval of ECo G Assistant™ Fatima Gulzar Sat, June 27, 2026 at 10:31 PM GMT+7 1 min read NPCE Neuro Pace, Inc.
- Food and Drug Administration approval for ECo G Assistant, the first "AI-driven clinician-enabled feature." It is designed to help epilepsy care using long-term intracranial EEG data.
- Chief Medical Officer Martha Morrell said the feature "represents an important advancement," with faster access to insights for more informed care.
Neuro Pace, Inc. (NPCE) Reveals FDA Approval of ECo G Assistant™ Fatima Gulzar Sat, June 27, 2026 at 10:31 PM GMT+7 1 min read NPCE Neuro Pace, Inc. (NASDAQ:NPCE) is one of the 10 Best Brain-Computer Interface Stocks to Buy.
On May 29, Neuro Pace, Inc. (NASDAQ:NPCE) said it received U.S. Food and Drug Administration approval for ECo G Assistant, the first "AI-driven clinician-enabled feature." It is designed to help epilepsy care using long-term intracranial EEG data.
Built on 124,450 epileptologist-labeled records, the company reported that the tool has "ECoGs of Interest." It allows physicians to review trends and timing patterns across months through integrated reports and charts, improving efficiency in data review and treatment decisions.